V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

  • Awaiting development
  • GID-TA11881
  • Expected publication date: TBC

27552-V940-Pembrolizumab-for-Melanoma-V1.0-SEP2025-NON-CONF.pdf